LATEST UPDATES » Vol 25, No. 09, September 2021 – The Rise of Alternative Proteins       » The Key to Improving Iron Content in Crops       » Breeding Non-GMO Plants With Next-Generation Chloroplast Gene-Editing       » New Lipomer Can Now Safely Deliver RNA Drugs to Lungs       » Preventing Deadly Post-Transplant Infection With Llama Nanobodies       » Insulin-Producing Implants: The Future of Care for Type 1 Diabetes      
Vol 25, No. 07, July 2021   |   Issue PDF view/purchase
Untangling the Twists of Alzheimer’s Plaques
Researchers from Duke-NUS Medical School and Monash University have uncovered the mechanism behind microglial phagocytosis of amyloid proteins, one of the root causes of Alzheimer’s disease.

With over 50 million people worldwide estimated to suffer from dementia in 2020, and these numbers predicted to skyrocket to 152 million by 2050, dementia has become a public health priority requiring urgent action. Amongst the many types of dementia, Alzheimer’s disease is one of the most prevalent forms, distinctive in its association with amyloid plaques that accumulate in the brain.

Under normal circumstances, the microglia, a type of glial cells located in the brain and spinal cord, serve as immune sentinels that remove foreign invaders and maintain brain homeostasis. While they are known to play a crucial role in clearing toxic substances such as amyloid plaques, their exact role in Alzheimer’s disease has remained shrouded in mystery. That is, up until recently.

A team of researchers from Duke-NUS Medical School and Monash University have recently discovered novel gene expression signatures fundamental in microglia’s role in engulfing amyloid proteins in the brain, a process otherwise known as amyloid plaque phagocytosis. This discovery can potentially pave the way for new targets of intervention to tackle Alzheimer’s.

While the team was examining changes in gene expression in specific human brain cells linked to the development of Alzheimer's disease, they decided to primarily focus on the microglia. Using a stain called methoxy-XO4, they studied microglia that have engulfed amyloid plaques from preclinical models of Alzheimer’s disease to assess its gene expression. They compared these observations with microglia that have not taken up amyloids to identify distinguishing genetic features that allow for its macrophagic capabilities.

"We sought to understand the molecular mechanisms and differences between microglia that were actively engulfing amyloid plaques in Alzheimer's disease and those that weren't," said Associate Professor Enrico Petretto from Duke-NUS's Cardiovascular and Metabolic Disorders Programme, a co-senior author of the study.

Based on their findings, they concluded that before engulfing amyloids, the microglia exhibited gene expression patterns similar to aged ones that are recognised as dysfunctional and a key player in causing Alzheimer’s. After they have taken up amyloid plaques, they displayed a distinct gene expression signature, partly engendered by a specific gene called Hif1a. This marked alteration, characterised by increased expression of Hif1a, was found to enhance the ability of microglia to devour amyloid proteins. Vice versa, decreasing Hif1a reduces microglia’s macrophagic properties for amyloids.

Unlocking the regulatory potential of Hif1a may also be the key to better understand the role of microglia in discarding obsolete or impaired synapses. Professor Petretto suspects that this initially protective defence mechanism can be disrupted as the disease progresses, thus impacting amyloid plaque phagocytosis.

In a bid to explore novel targets for drug development, the researchers also utilised computational models to forecast molecular networks associated with microglia phagocytosis of proteins. They made a surprising discovery of how the common immunosuppressant rapamycin can inhibit the gene Hif1A from promoting microglia amyloid plaque phagocytosis.

"This relationship between Hif1a and cognitive decline in Alzheimer's disease is yet to be comprehensively uncovered," said PhD student Gabriel Chew, who is a co-first author of the paper. "Future work could focus on using gene-editing tool CRISPR to test the impact of manipulating Hif1a on symptom severity and disease progression."

Source: Grubman et al. (2021). Transcriptional signature in microglia associated with Aβ plaque phagocytosis. Nature Communications, 12(1), 1-22.

news TechInnovation 2021 Virtual Exhibition to Showcase Sustainable Energy, Food, and Healthcare Solutions
news A New Approach for Effective Gout Treatment
news TechInnovation Returns from 28 to 30 September 2021
news Singapore Health & Biomedical Congress 2021 is Set to Brave the New Frontiers as We Revolutionise and Transform Healthcare

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2021 World Scientific Publishing Co Pte Ltd  •  Privacy Policy